Changes of body weight and inflammatory markers after 12-Week intervention trial: Results of a double-blind, placebo-control pilot study

Yonsei Medical Journal

Volumn 52, Issue 2, 2011, Pages 242-248

  Joo, Nam Seok ^a   Kim, Sang Man ^b   Kim, Kwang Min ^a   Kim, Chan Won ^a   Kim, Bom Taeck ^a   Lee, Duck Joo ^a  

^a Ajou University School of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Adiponectin; Anti inflammatory agent; Inflammation; TNF

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; DIACEREIN; PLACEBO; SIBUTRAMINE;

ANTHROPOMETRY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MALE; METABOLIC PARAMETERS; OBESITY; PILOT STUDY; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION;

ABSORPTIOMETRY, PHOTON; ADIPONECTIN; ADULT; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; APPETITE DEPRESSANTS; C-REACTIVE PROTEIN; CYCLOBUTANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MALE; OBESITY; PILOT PROJECTS; TUMOR NECROSIS FACTOR-ALPHA; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 79952800798     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2011.52.2.242     Document Type: Article

References (28)

1. Korean Ministry of Health and Welfare. Report on National Health and Nutrition Survey 2005. Seoul: Korean Ministry of Health and Welfare; 2006.
2. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body mass index and mortality in Korean men and women. N Engl J Med 2006;355:779-87.
3. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
4. Cook DG, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000;149:139-50.
5. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.
6. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
7. Romalho R, Guimarães C. [The role of adipose tissue and macrophages in chronic inflammation associated with obesity]. Acta Med Port 2008;21:489-96.
8. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173:309-14.
9. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-76.
10. Thomson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body mass index and future healthcare costs: a retrospective cohort study. Obes Res 2001;9:210-8.
11. Tamura T, Ohmori K. Diacerein suppresses the increase in plasma nitric oxide in rat adjuvant-induced arthritis. Eur J Pharmacol 2001;419:269-74.
12. Tamura T, Shirai T, Kosaka N, Ohmori K, Takafumi N. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol 2002;448:81-7.
13. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000;43:2339-48.
14. Nguyen M, Dougados M, Berdah L, Amor B. Diacerein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994;37: 529-36.
15. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
16. Mohanty P, Aljada AS, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35.
17. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002;25:542-9.
18. Kasim-Karakas SE, Tsodikov A, Singh U, Jialal I. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am J Clin Nutr 2006;83:774-9.
19. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 2004;117:398-405.
20. Manigrasso MR, Ferroni P, Santilli F, Taraborelli T, Guagnano MT, Michetti N, et al. Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab 2005;90:5876-9.
21. Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, et al. The differential effects of metformin on markers of endothelail activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled randomized clinical trial. J Clin Endocrionol Metab 2004;89:3943-8.
22. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, Loeser RF, et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr 2004;79:544-51.
23. Risérus U, Vessby B, Arnlöv J, Basu S. Effects of cis-9, trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. Am J Clin Nutr 2004;80:279-83.
24. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804.
25. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9.
26. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
27. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101: 1767-72.
28. Stefen N, Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res 2002;34:469-74.